Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction

European Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2014, Pages 527-530

  Poh, Kian Keong ^a,b   Xu, Xin ^c   Chan, Mark Y ^a,b   Lee, Chi Hang ^a,b   Tay, Edgar L ^a,b   Low, Adrian F ^a,b   Chan, Koo Hui ^a,b   Sia, Winnie ^a   Tang, Liang Qiu ^c   Tan, Huay Cheem ^a,b   Lui, Charles Y ^d   Nguyen, Vincent ^e   Fujise, Kenichi ^e   Huang, Ming He ^e,f  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SHANTOU UNIVERSITY   (China)

^d UNIVERSITY OF UTAH   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f Gulf Coast Heart Clinic League City   (United States)

Author keywords

acute myocardial infarction; esmolol; milrinone; reperfusion injury

Indexed keywords

CREATINE KINASE MB; ESMOLOL; MILRINONE; PLACEBO; PROPANOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PULSE PRESSURE; QRS COMPLEX; REPERFUSION INJURY; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MILRINONE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; PROPANOLAMINES;

EID: 84898884502     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1650-9     Document Type: Article

References (15)

1. Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, Gurm HS (2013) Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 369:901-909
2. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway (review). Cardiovasc Res 61:448-460
3. Hausenloy DJ, Yellon DM (2008) Time to take myocardial reperfusion injury seriously. N Engl J Med 359:518-520
4. Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K et al (2005) Outcome of patients aged >75 years in the should we emergently revascularize occluded coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J 149:1128-1134
5. Denktas AE, Anderson HV, McCarthy J, Smalling RW (2011) Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care (review). J Am Coll Cardiol Intv 4:599-604
6. Gerczuk PZ, Kloner RA (2012) An update on cardioprotection. A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials (review). J Am Coll Cardiol 59:969-978
7. Huang MH, Wu Y, Nguyen V, Rastogi S, McConnell BK, Wijaya C et al (2011) Heart Protection by combination therapy with milrinone and esmolol at early reperfusion during acute myocardial infarction. Cardiovasc Drugs Ther 25:223-232
8. Huang MH, Nguyen V, Rastogi S, Wu Y, Birnbaum Y, Lin Y et al (2007) Post-ischemic therapy with calcitonin gene-related peptide and β2-adrenergic receptor agonist confers synergistic infarct size reduction. Circ Res (abstract)101:1210
9. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S et al (2001) Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitor: the role of protein kinases A and p38 mitogen-activated protein kinase. Circulation 104:705-710
10. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R (2009) Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand 53:941-948
11. Matsumoto S, Cho S, Tosaka S, Higashijima U, Maekawa T, Hara T, Sumikawa K (2012) Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. Cardiovasc Diabetol 11:4
12. Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New Engl J Med 339:489-497
13. Huang MH, Nguyen V, Wu Y, Rastogi S, Birnbaum Y, Lui CY et al (2009) Reducing ischemia/reperfusion injury through δ-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling. Cardiovasc Res 84:452-460
14. Nishiki T, Kitada H, Okabe Y, Miura Y, Kurihara K, Kawanami S, Tanaka M (2011) Effect of milrinone on ischemia-reperfusion injury in the rat kidney. Transplant Proc 43:1489-1494
15. Toyoda T, Tosaka S, Tosaka R, Maetawa T, Cho S, Eguchi S, Nakashima M, Sumikawa K (2014) Milrinone-induced postconditioning reduces hepatic ischemia-reperfusion injury in rats: the roles of phosphatidylinositol 3-kinase and nitric oxide. J Surg Res 186:446-451